Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1997

01-06-1997 | ORIGINAL ARTICLE

Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

Authors: David J. Stewart, Corinne S. Dulberg, Nadia Z. Mikhael, M. Deidre Redmond, Vital A. J. Montpetit, Rakesh Goel

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1997

Login to get access
Metadata
Title
Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods
Authors
David J. Stewart
Corinne S. Dulberg
Nadia Z. Mikhael
M. Deidre Redmond
Vital A. J. Montpetit
Rakesh Goel
Publication date
01-06-1997
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1997
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050661

Other articles of this Issue 4/1997

Cancer Chemotherapy and Pharmacology 4/1997 Go to the issue

CLINICAL TRIAL REPORT

A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer

SHORT COMMUNICATION

Protective role of metallothionein in renal toxicity of cisplatinum

ORIGINAL ARTICLE

Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial

ORIGINAL ARTICLE

The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue

ORIGINAL ARTICLE

Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes

ORIGINAL ARTICLE

Bladder tissue pharmacokinetics of intravesical taxol
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits